Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Amiodarone Dosage for Atrial Fibrillation with Rapid Ventricular Response

Intravenous (IV) Amiodarone Dosing Protocol

  • The American Heart Association recommends an initial intravenous amiodarone dosage of 150 mg given over 10 minutes, which may be repeated if necessary, followed by a 1 mg/min infusion for 6 hours, then 0.5 mg/min for 18 hours, with a total 24-hour dose not exceeding 2.2 g 1, 2
  • The initial loading dose is 150 mg IV bolus administered over 10 minutes, and may be repeated in 10-30 minutes if necessary for inadequate response 1, 3
  • The maintenance infusion is 1 mg/min for 6 hours (360 mg), then reduced to 0.5 mg/min for 18 hours (540 mg) 1, 4

Oral Amiodarone for Continued Management

  • For patients who received IV amiodarone for less than one week, the American College of Cardiology recommends 800-1,600 mg oral amiodarone daily in divided doses 3
  • For long-term maintenance, the American College of Cardiology recommends 200 mg daily after a loading period (typically after a total of 10 g has been given) 3, 5

Efficacy and Onset of Action

  • The antiarrhythmic effect of amiodarone begins in less than 30 minutes 3
  • Conversion to sinus rhythm occurs in approximately 46-50% of patients within the first 30 minutes 3

Monitoring Requirements

  • Continuous ECG monitoring is required during administration, as recommended by the American Academy of Pediatrics 6
  • Regular blood pressure monitoring is necessary to detect hypotension, as recommended by the American Heart Association 1
  • Monitoring for bradycardia and AV block is also necessary, as recommended by the American Academy of Family Physicians 3

Potential Adverse Effects

  • Hypotension, especially with rapid administration, is a potential adverse effect, as reported by the American Heart Association and the American Academy of Family Physicians 1, 3
  • Bradycardia and atrioventricular block are also potential adverse effects, as reported by the American Heart Association and the American Academy of Family Physicians 1, 3
  • Phlebitis, particularly with concentrations >2 mg/mL, is a potential adverse effect, as reported by the American Heart Association 1
  • QT prolongation, with longer-term use, is a potential adverse effect, as reported by the American Academy of Family Physicians 3

Special Considerations

  • For long-term therapy, the American Academy of Family Physicians recommends using the lowest effective dose to minimize toxicity risk 3
  • Amiodarone has a very long half-life (IV: 9-36 days; Oral: 26-107 days), which affects dosing strategies for long-term management, as reported by the American College of Cardiology 2

Amiodarone Dose Management

Introduction to Dose Adjustment

  • If heart rate falls below 50 beats per minute with worsening symptoms, halve the amiodarone dose, according to the European Society of Cardiology 7, 8
  • Review and consider discontinuing other heart rate-slowing medications before reducing amiodarone, as recommended by the European Society of Cardiology 7, 8
  • Obtain an ECG to exclude heart block, as suggested by the European Society of Cardiology 7, 8
  • Seek specialist advice if symptoms persist after dose reduction, as advised by the European Society of Cardiology 7, 8

Maintenance Dose Strategy

  • Standard maintenance ranges from 100-200 mg daily for most arrhythmias, according to the American Heart Association 9
  • The long half-life of amiodarone (averaging 58 days, range 15-100 days) means effects persist long after dose changes, as reported by the American Academy of Family Physicians 10, 11

Critical Warnings

  • Beta-blockers and amiodarone should not be stopped suddenly unless absolutely necessary, as warned by the European Society of Cardiology 7, 8
  • There is risk of rebound myocardial ischemia, infarction, and arrhythmias with sudden discontinuation, according to the European Society of Cardiology 7, 8
  • Ideally, seek specialist advice before treatment discontinuation, as recommended by the European Society of Cardiology 7, 8

Monitoring Requirements

  • Monitor heart rate, blood pressure, and clinical status closely after any dose change, as suggested by the European Society of Cardiology 7, 8
  • Continue surveillance for thyroid dysfunction, pulmonary toxicity, and hepatic toxicity at least every 6 months, as advised by the American Academy of Family Physicians 10

Drug Interaction Considerations

  • Reduce warfarin dose by 50% and digoxin dose by 30-50% when starting amiodarone, as recommended by the American Heart Association 9
  • Avoid combining with other QT-prolonging drugs without expert consultation, as warned by the American Heart Association 9
  • Grapefruit juice can inhibit metabolism and elevate amiodarone levels, as reported by the American Academy of Family Physicians 10, 11

REFERENCES